Life Sciences Index 2024

Welcome to the first edition of the Life Sciences Index, a study about perceptions of innovation and growth in the life sciences industry. The survey explores the current drivers of – and barriers to – innovation and growth by the world’s largest biopharma and medtech companies.

We surveyed 200 industry leaders from the world’s top biopharma and medtech companies and asked for their insights on the market environment for incentivising innovation and growth, including four specific themes: dealmaking, sustainability and ESG, intelligent technology and the future of care delivery.

The result is a comprehensive state of the market report, published every two years, that will track perceptions of innovation and growth over time.

The overall Life Sciences Index Score for 2024 is 5.3 out of 7. This means respondents view the global life sciences industry as somewhat attractive for incentivising innovation and growth.

Some key findings from the Index include:

• Only 36% of respondents believe leveraging artificial intelligence and machine learning is a strategic priority.
• 49% predict deal activity to increase over the next 12 months, while 43% think it will stay broadly the same.
• Only 13% say that ESG is a strategic priority for their business.
• 79% strongly agree that innovators will routinely offer holistic packages of patient and HCP support.
• The top three markets for fostering innovation and growth are the US, EU and China.

Our global Life Sciences team will be holding a series of exclusive roundtable events to give you an opportunity to discuss the findings of the Index with your peers. We have a limited number of seats available at each event. If you would like to attend, please contact LifeSciencesIndex2024@dlapiper.com.

• Warsaw, Poland – 4 December 2024
• Brussels, Belgium
• Dublin, Ireland
• Paris, France
• Shanghai, China
• Sydney, Australia
• Warsaw, Poland